PMID- 38326563
OWN - NLM
STAT- MEDLINE
DCOM- 20240325
LR  - 20240325
IS  - 1759-4782 (Electronic)
IS  - 1759-4774 (Linking)
VI  - 21
IP  - 4
DP  - 2024 Apr
TI  - Dendritic cells as orchestrators of anticancer immunity and immunotherapy.
PG  - 257-277
LID - 10.1038/s41571-024-00859-1 [doi]
AB  - Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate 
      immune cells that regulate adaptive immunity, including against cancer. 
      Therefore, understanding the precise activities of DCs in tumours and patients 
      with cancer is important. The classification of DC subsets has historically been 
      based on ontogeny; however, single-cell analyses are now additionally revealing a 
      diversity of functional states of DCs in cancer. DCs can promote the activation 
      of potent antitumour T cells and immune responses via numerous mechanisms, 
      although they can also be hijacked by tumour-mediated factors to contribute to 
      immune tolerance and cancer progression. Consequently, DC activities are often 
      key determinants of the efficacy of immunotherapies, including immune-checkpoint 
      inhibitors. Potentiating the antitumour functions of DCs or using them as tools 
      to orchestrate short-term and long-term anticancer immunity has immense but 
      as-yet underexploited therapeutic potential. In this Review, we outline the 
      nature and emerging complexity of DC states as well as their functions in 
      regulating adaptive immunity across different cancer types. We also describe how 
      DCs are required for the success of current immunotherapies and explore the 
      inherent potential of targeting DCs for cancer therapy. We focus on novel 
      insights on DCs derived from patients with different cancers, single-cell studies 
      of DCs and their relevance to therapeutic strategies.
CI  - (c) 2024. Springer Nature Limited.
FAU - Heras-Murillo, Ignacio
AU  - Heras-Murillo I
AD  - Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares 
      (CNIC), Madrid, Spain.
FAU - Adan-Barrientos, Irene
AU  - Adan-Barrientos I
AD  - Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares 
      (CNIC), Madrid, Spain.
FAU - Galan, Miguel
AU  - Galan M
AD  - Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares 
      (CNIC), Madrid, Spain.
FAU - Wculek, Stefanie K
AU  - Wculek SK
AUID- ORCID: 0000-0001-5565-8561
AD  - Innate Immune Biology Laboratory, Institute for Research in Biomedicine (IRB 
      Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, 
      Spain. stefanie.wculek@irbbarcelona.org.
FAU - Sancho, David
AU  - Sancho D
AUID- ORCID: 0000-0003-2890-3984
AD  - Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares 
      (CNIC), Madrid, Spain. dsancho@cnic.es.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240207
PL  - England
TA  - Nat Rev Clin Oncol
JT  - Nature reviews. Clinical oncology
JID - 101500077
SB  - IM
MH  - Humans
MH  - *Neoplasms/therapy
MH  - Adaptive Immunity
MH  - Immunotherapy
MH  - Immune Tolerance
MH  - Dendritic Cells
EDAT- 2024/02/08 00:42
MHDA- 2024/03/25 06:44
CRDT- 2024/02/07 23:27
PHST- 2024/01/09 00:00 [accepted]
PHST- 2024/03/25 06:44 [medline]
PHST- 2024/02/08 00:42 [pubmed]
PHST- 2024/02/07 23:27 [entrez]
AID - 10.1038/s41571-024-00859-1 [pii]
AID - 10.1038/s41571-024-00859-1 [doi]
PST - ppublish
SO  - Nat Rev Clin Oncol. 2024 Apr;21(4):257-277. doi: 10.1038/s41571-024-00859-1. Epub 
      2024 Feb 7.